NCT06588322View on ClinicalTrials.gov

Detection of Homologous Recombination Pathway Gene Mutations in Circulating Tumour DNA From BRCA-mutated Ovarian Cancer Patients Receiving First-line PARP Inhibitor Maintenance Therapy

NARecruitingINTERVENTIONAL
Enrollment

130

Participants

Timeline

Start Date

January 8, 2025

Primary Completion Date

November 30, 2029

Study Completion Date

November 30, 2029

Conditions
Ovarian Cancer
Interventions
OTHER

Blood samples will be taken on several times (36 mL of blood taken at each time):

"* Inclusion visit (T0): prior to initiation of Olaparib treatment~* Follow-up period (T1 to T8): every 3 months for a maximum of 24 months~* End of study (Tx): on definitive cessation of Olaparib treatment for any reason (progression, toxicity or definitive cessation of treatment after 2 years)."

Trial Locations (6)

Unknown

RECRUITING

INSTITUT DE CANCEROLOGIE DE L'OUEST - Site Angers, Angers

RECRUITING

Institut Bergonie, Bordeaux

RECRUITING

Chu de Limoges, Limoges

RECRUITING

Chu de Nimes, Nîmes

RECRUITING

INSTITUT DE CANCEROLOGIE DE L'OUEST - Site Saint-Herblain, Saint-Herblain

RECRUITING

IUCT-O, Toulouse

All Listed Sponsors
lead

Institut Claudius Regaud

OTHER